NCT05996952View on ClinicalTrials.gov

RC48-ADC in Adjuvant/Salvage Treatment of HER2 Positive Non-muscle-invasive Bladder Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

August 31, 2023

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2026

Conditions
Non-muscle Invasive Bladder Cancer
Interventions
DRUG

RC48-ADC

Patients are treated with RC48-ADC at 2.0 mg/kg as an intravenous infusion over 30-90 minutes (60 minutes is recommended) once every 2 weeks for 12 weeks.

Trial Locations (1)

610041

West China Hospital, Chengdu

All Listed Sponsors
collaborator

RemeGen Co., Ltd.

INDUSTRY

lead

West China Hospital

OTHER

NCT05996952 - RC48-ADC in Adjuvant/Salvage Treatment of HER2 Positive Non-muscle-invasive Bladder Cancer | Biotech Hunter | Biotech Hunter